• Dr. Caius Radu

    SOURCE

    April, 2016

    New method could lead to better therapies for many deadly cancers

    A promising new discovery by UCLA scientists could lead to a new method of identifying cancer patients that express high levels of an enzyme and are more likely to respond to cancer treatments.

    Decades of significant advances and improvements in PET imaging technology have led to the detection of an enzyme in humans that plays a significant role in DNA formation, the building blocks of life. The enzyme, called deoxycytidine kinase (dCK), was previously found to be highly expressed in acute leukemia cells and in activated lymphocytes and controls a critical step in the nucleoside salvage pathway, an important therapeutic and PET imaging target in cancer.

    The study will be published online March 28 in the journal Proceedings of the National Academy of Sciences of the United States of America.

    In a seven-year study, a team of UCLA researchers led by Dr. Caius Radu, a UCLA Jonsson Comprehensive Cancer Center member and a professor in the Department of Molecular and Medical Pharmacology, developed a highly sophisticated PET probe called [18F]CFA that is capable of detecting dCK activity in humans for the first time.

    “The quality of the images is much better,” said Radu. “We are able to clearly see tissues, including tumor tissues, with high dCK activity that we haven’t seen before in humans using any of the other probes previously developed for this enzyme.”

    Positron emission tomography (PET) is a noninvasive imaging technology that uses a radioactive substance, called PET probe, to look for disease in the body and it also shows how organs and tissues are functioning. Until recently, PET technology was only able to clearly detect dCK in mice due to metabolic instability of the previous probes and cross-reactivity with a dCK-related enzyme in humans.

    The dCK enzyme plays an integral role in allowing drugs such as Clofarabine, Cytarabine and Fludarabine to treat certain types of leukemia and others like Gemcitabine to treat breast, ovarian, non-small cell lung and pancreatic cancers.

    “This enzyme is essential for the therapeutic activity of an entire class of anticancer drugs and even for some antiviral drugs,” said Radu, who is also a member of the UCLA Broad Stem Cell Research Center. “It can take an inactive drug and activate it. If you trick a cancer cell or virus to activate the drug, it would be toxic for the cancer cell or viral genome.”

    Since activated immune cells increase their expression of the dCK enzyme, [18F]CFA could also be used to monitor the effectiveness of immunotherapeutic interventions, said Radu.

    The researchers hope to begin clinical trials with the [18F]CFA in the near future. He and his colleagues will eventually seek an approval by the U.S. Food & Drug Administration.

    (Radu and his team are co-founders of Sofie Biosciences and they are the inventors of [18F]CFA and analogs, which were patented by the University of California and have been licensed to Sofie Biosciences. University of California also patented additional intellectual property for small molecule dCK inhibitors.)

     
     

    No comments

    Be the first one to leave a comment.

    Post a Comment


     

     

    Latest Posts

    Latest Video

     
     

    LATEST POSTS

    First FDA Approval For Clinical Cloud-Based Deep Learning In Healthcare

     SOURCE: FORBES The first FDA approval for a machine learning application to be used in a clinical setting is a…

    FDA-approved study uses adipose stem cells for treatment of shoulder injuries

    SOURCE Sanford Health is conducting the first clinical trial approved by the FDA to treat injured shoulders using patients’ adipose…

    Could Anatomics BioModel Stereotaxy replace navigation or a robot?

    SOURCE Paul S D’Urso Neurosurgeon & Founder of Anatomics Because 3D printing is so accurate I was able to locate…

    $250 million awarded to new Advanced Robotics Manufacturing Innovation Hub

    SOURCE Headquartered in Pittsburgh, PA, the new institute is made up of governments, industry, academia, and non-profit organizations from across the country….

    Self-assembling 3D printing inks produce more true-to-life tissue

    SOURCE Biological and chemical researchers are developing 3D printable inks capable of self-assembly, i.e. forming a shape based on a…

    Urine Exosomes – An Emerging Trove of Biomarkers

     SOURCE Exosomes are released by most cells and can be isolated from all biofluids including urine. Exosomes are small vesicles…

    What is machine learning?

    SOURCE In this fascinating animation from Oxford Sparks, we take a look at how statistics and computer science can be used to…

    Catalia Health uses social robots to improve health outcomes

    Credit: Catalia Health SOURCE Catalia Health is leading the surge in social robotics, with Mabu, their patient care management system. Catalia…